RU2003130093A - 4-(2-бутиламино)-2,7-диметил-8-(2-метил-6-метоксипирид-3-ил) пиразоло-[1,5-а]-1,3,5-триазин, его энантиомеры и фармацевтически приемлемые соли в качестве лигандов рецепторов рилизинг- фактора кортикотропина - Google Patents
4-(2-бутиламино)-2,7-диметил-8-(2-метил-6-метоксипирид-3-ил) пиразоло-[1,5-а]-1,3,5-триазин, его энантиомеры и фармацевтически приемлемые соли в качестве лигандов рецепторов рилизинг- фактора кортикотропина Download PDFInfo
- Publication number
- RU2003130093A RU2003130093A RU2003130093/04A RU2003130093A RU2003130093A RU 2003130093 A RU2003130093 A RU 2003130093A RU 2003130093/04 A RU2003130093/04 A RU 2003130093/04A RU 2003130093 A RU2003130093 A RU 2003130093A RU 2003130093 A RU2003130093 A RU 2003130093A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- compound according
- crf
- pharmaceutically acceptable
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
Claims (17)
1. Соединение формулы (I):
его изомеры, стереоизомерные формы или смеси его стереоизомерных форм, его фармацевтически приемлемые пролекарства или фармацевтически приемлемые солевые формы.
2. Соединение по п.1, его фармацевтически приемлемые пролекарства или фармацевтически приемлемые солевые формы, где указанное соединение представляет собой 4-((R)-2-бутиламино)-2,7-диметил-8-(2-метил-6-метоксипирид-3-ил)[1,5-a]пиразоло-1,3,5-триазин.
3. Соединение по п.1, его фармацевтически приемлемые пролекарства или фармацевтически приемлемые солевые формы, где указанное соединение по существу не содержит его (S) стереоизомер.
4. Соединение по п.1, где указанное соединение представляет собой 4-(2-бутиламино)-2,7-диметил-8-(2-метил-6-метоксипирид-3-ил)[1,5-a]пиразоло-1,3,5-триазин.
5. Соединение по п.1, где указанное соединение представляет собой 4-((R)-2-бутиламино)-2,7-диметил-8-(2-метил-6-метоксипирид-3-ил)[1,5-a]пиразоло-1,3,5-триазин.
6. Фармацевтическая композиция, включающая фармацевтически приемлемый носитель и терапевтически эффективное количество соединения по п.1.
7. Фармацевтическая композиция, включающая фармацевтически приемлемый носитель и терапевтически эффективное количество соединения по п.5.
8. Способ антагонистического воздействия на рецептор CRF у млекопитающего, включающий введение млекопитающему терапевтически эффективного количества соединения по п.1.
9. Способ лечения расстройства, проявляющегося гиперсекрецией CRF у теплокровного животного, включающий введение животному терапевтически эффективного количества соединения по п.1.
10. Способ лечения расстройства, лечение которого можно осуществить или облегчить антагонистическим воздействием на CRF, включающий введение млекопитающему терапевтически эффективного количества соединения по п.1.
11. Способ антагонистического воздействия на рецептор CRF у млекопитающего, включающий введение млекопитающему терапевтически эффективного количества соединения по п.5.
12. Способ лечения тревоги или депрессии у млекопитающих, включающий введение млекопитающему терапевтически эффективного количества соединения по п.1.
13. Способ лечения тревоги или депрессии у млекопитающих, включающий введение млекопитающему терапевтически эффективного количества соединения по п. 5.
14. Способ скрининга для выявления лигандов рецепторов CRF, причем способ включает: а) проведение анализа конкурентного связывания с рецептором CRF количества соединения по п.1, которое мечено выявляемой меткой, и потенциального лиганда; и b) определение способности указанного потенциального лиганда заместить указанное меченое соединение.
15. Способ выявления рецепторов CRF в ткани, включающий: а) обеспечение контакта соединения по п.1, которое мечено выявляемой меткой, с тканью при условиях, которые обеспечивают возможность связывания соединения с тканью; и b) выявление меченого соединения, связанного с тканью.
16. Способ ингибирования связывания CRF с рецептором CRF-1, включающий обеспечение контакта соединения по п.1 с раствором, включающим клетки, экспрессирующие рецептор CRF1, причем соединение присутствует в растворе в концентрации, достаточной для ингибирования связывания CRF с рецептором CRF-1.
17. Изделие, включающее: а) упаковочный материал; b) соединение по п.1; и с) этикетку или вкладыш упаковки, содержащийся внутри указанного упаковочного материала и указывающий, что указанное соединение эффективно для лечения тревоги или депрессии.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27540301P | 2001-03-13 | 2001-03-13 | |
| US60/275,403 | 2001-03-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003130093A true RU2003130093A (ru) | 2005-03-20 |
| RU2292347C2 RU2292347C2 (ru) | 2007-01-27 |
Family
ID=23052141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003130093/04A RU2292347C2 (ru) | 2001-03-13 | 2002-03-06 | 4-(2-БУТИЛАМИНО)-2,7-ДИМЕТИЛ-8-(2-МЕТИЛ-6-МЕТОКСИПИРИД-3-ИЛ)ПИРАЗОЛО-[1,5-а]-1,3,5-ТРИАЗИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕГО СОДЕРЖАЩАЯ, И ЕГО ПРИМЕНЕНИЕ |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US20030125330A1 (ru) |
| EP (1) | EP1368094B1 (ru) |
| JP (1) | JP4549630B2 (ru) |
| KR (1) | KR100875595B1 (ru) |
| CN (1) | CN100427093C (ru) |
| AR (1) | AR032986A1 (ru) |
| AT (1) | ATE355102T1 (ru) |
| AU (1) | AU2002245605B2 (ru) |
| BG (1) | BG66331B1 (ru) |
| BR (1) | BR0208357A (ru) |
| CA (1) | CA2440553C (ru) |
| CY (1) | CY1106607T1 (ru) |
| CZ (1) | CZ20032481A3 (ru) |
| DE (1) | DE60218434T2 (ru) |
| DK (1) | DK1368094T3 (ru) |
| EE (1) | EE05433B1 (ru) |
| ES (1) | ES2282401T3 (ru) |
| GE (1) | GEP20053608B (ru) |
| HK (1) | HK1057182A1 (ru) |
| HR (1) | HRP20030822B1 (ru) |
| HU (1) | HU229317B1 (ru) |
| IL (2) | IL157615A0 (ru) |
| IS (1) | IS2839B (ru) |
| MX (1) | MXPA03008185A (ru) |
| MY (1) | MY146935A (ru) |
| NO (1) | NO328580B1 (ru) |
| NZ (1) | NZ528207A (ru) |
| PL (1) | PL208278B1 (ru) |
| PT (1) | PT1368094E (ru) |
| RS (1) | RS50863B (ru) |
| RU (1) | RU2292347C2 (ru) |
| SK (1) | SK287603B6 (ru) |
| TW (1) | TWI257388B (ru) |
| UA (1) | UA74634C2 (ru) |
| WO (1) | WO2002072202A1 (ru) |
| ZA (1) | ZA200306995B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094782B1 (en) * | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
| US20030125330A1 (en) * | 2001-03-13 | 2003-07-03 | Gilligan Paul J. | 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| AR041470A1 (es) * | 2002-10-17 | 2005-05-18 | Upjohn Co | Compuestos de pirrolo (1,2 - b) piridazina y sus usos |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7041671B2 (en) | 2003-04-02 | 2006-05-09 | Pfizer Inc | Pyrrolo[1,2-b]pyridazine compounds and their uses |
| US7056920B2 (en) | 2003-04-04 | 2006-06-06 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| US7034023B2 (en) * | 2003-04-04 | 2006-04-25 | Pfizer Inc | Pyrrolo[1,2-B]pyridazine compounds and their uses |
| JP2006523675A (ja) * | 2003-04-15 | 2006-10-19 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ピロロ［１，２−ｂ］ピリダジン化合物及びそれらの使用 |
| US7153961B2 (en) | 2003-11-25 | 2006-12-26 | Bristol-Myers Squibb Pharma Co. | Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist |
| US7208596B2 (en) * | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
| US8030304B2 (en) | 2006-09-20 | 2011-10-04 | Eli Lilly And Company | Thiazole pyrazolopyrimidines CRF1 receptor antagonists |
| EP2841068B8 (en) * | 2012-04-23 | 2019-03-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
| KR102079844B1 (ko) * | 2016-09-20 | 2020-02-20 | 가톨릭대학교 산학협력단 | 담석 용해제를 포함하는 담낭 질환 치료용 약학 조성물 |
| BR112023002497A2 (pt) | 2020-08-12 | 2023-05-02 | Spruce Biosciences Inc | Métodos e composições para tratamento da síndrome dos ovários policísticos |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
| JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| JP2000507552A (ja) | 1996-03-26 | 2000-06-20 | デュポン ファーマシューティカルズ カンパニー | アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体 |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| WO1997044308A1 (en) | 1996-05-24 | 1997-11-27 | The Dow Chemical Company | Process for preparing aliphatic ester compounds and alkanols |
| PL195762B1 (pl) * | 1996-07-24 | 2007-10-31 | Bristol Myers Squibb Pharma Co | Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku |
| US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| EP0915880B1 (en) | 1996-07-24 | 2007-10-10 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
| AU735401B2 (en) * | 1996-08-28 | 2001-07-05 | Pfizer Inc. | Substituted 6,5-hetero-bicyclic derivatives |
| UA62972C2 (en) | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
| AU746706B2 (en) | 1997-07-03 | 2002-05-02 | Du Pont Pharmaceuticals Company | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| CA2296014A1 (en) | 1997-07-03 | 1999-01-14 | Frank W. Hobbs | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| IL134748A0 (en) | 1997-09-02 | 2001-04-30 | Du Pont Pharm Co | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| SI1049699T1 (en) * | 1998-01-28 | 2004-10-31 | Bristol-Myers Squibb Pharma Company | Pyrazolotriazines as crf antagonists |
| US6194410B1 (en) * | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| JP2002510695A (ja) | 1998-04-03 | 2002-04-09 | デュポン ファーマシューティカルズ カンパニー | 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン |
| US6124463A (en) | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
| US20030125330A1 (en) * | 2001-03-13 | 2003-07-03 | Gilligan Paul J. | 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
-
2002
- 2002-03-06 US US10/092,312 patent/US20030125330A1/en not_active Abandoned
- 2002-03-06 PL PL368644A patent/PL208278B1/pl unknown
- 2002-03-06 AU AU2002245605A patent/AU2002245605B2/en not_active Ceased
- 2002-03-06 NZ NZ528207A patent/NZ528207A/en not_active IP Right Cessation
- 2002-03-06 HU HU0303480A patent/HU229317B1/hu not_active IP Right Cessation
- 2002-03-06 BR BR0208357-4A patent/BR0208357A/pt active Search and Examination
- 2002-03-06 RU RU2003130093/04A patent/RU2292347C2/ru not_active IP Right Cessation
- 2002-03-06 CA CA2440553A patent/CA2440553C/en not_active Expired - Fee Related
- 2002-03-06 DK DK02713776T patent/DK1368094T3/da active
- 2002-03-06 CN CNB028064151A patent/CN100427093C/zh not_active Expired - Fee Related
- 2002-03-06 EP EP02713776A patent/EP1368094B1/en not_active Expired - Lifetime
- 2002-03-06 MX MXPA03008185A patent/MXPA03008185A/es active IP Right Grant
- 2002-03-06 JP JP2002571157A patent/JP4549630B2/ja not_active Expired - Fee Related
- 2002-03-06 IL IL15761502A patent/IL157615A0/xx unknown
- 2002-03-06 SK SK1157-2003A patent/SK287603B6/sk not_active IP Right Cessation
- 2002-03-06 CZ CZ20032481A patent/CZ20032481A3/cs unknown
- 2002-03-06 RS YUP-715/03A patent/RS50863B/sr unknown
- 2002-03-06 DE DE60218434T patent/DE60218434T2/de not_active Expired - Lifetime
- 2002-03-06 PT PT02713776T patent/PT1368094E/pt unknown
- 2002-03-06 WO PCT/US2002/006837 patent/WO2002072202A1/en active IP Right Grant
- 2002-03-06 AT AT02713776T patent/ATE355102T1/de active
- 2002-03-06 KR KR1020037011913A patent/KR100875595B1/ko not_active IP Right Cessation
- 2002-03-06 ES ES02713776T patent/ES2282401T3/es not_active Expired - Lifetime
- 2002-03-06 GE GE5322A patent/GEP20053608B/en unknown
- 2002-03-06 EE EEP200300435A patent/EE05433B1/xx not_active IP Right Cessation
- 2002-03-12 MY MYPI20020879A patent/MY146935A/en unknown
- 2002-03-13 TW TW091104706A patent/TWI257388B/zh not_active IP Right Cessation
- 2002-03-13 AR ARP020100908A patent/AR032986A1/es not_active Application Discontinuation
- 2002-06-03 UA UA2003109244A patent/UA74634C2/ru unknown
-
2003
- 2003-02-05 US US10/358,652 patent/US7157578B2/en not_active Expired - Lifetime
- 2003-08-27 IL IL157615A patent/IL157615A/en not_active IP Right Cessation
- 2003-09-08 ZA ZA200306995A patent/ZA200306995B/en unknown
- 2003-09-10 IS IS6947A patent/IS2839B/is unknown
- 2003-09-11 NO NO20034023A patent/NO328580B1/no not_active IP Right Cessation
- 2003-09-23 BG BG108189A patent/BG66331B1/bg unknown
- 2003-10-10 HR HR20030822A patent/HRP20030822B1/xx not_active IP Right Cessation
-
2004
- 2004-01-02 HK HK04100028A patent/HK1057182A1/xx not_active IP Right Cessation
-
2006
- 2006-11-07 US US11/593,715 patent/US7358252B2/en not_active Expired - Lifetime
-
2007
- 2007-05-18 CY CY20071100678T patent/CY1106607T1/el unknown
-
2008
- 2008-02-13 US US12/030,439 patent/US7662817B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003130093A (ru) | 4-(2-бутиламино)-2,7-диметил-8-(2-метил-6-метоксипирид-3-ил) пиразоло-[1,5-а]-1,3,5-триазин, его энантиомеры и фармацевтически приемлемые соли в качестве лигандов рецепторов рилизинг- фактора кортикотропина | |
| Mazurek et al. | Nerve growth factor induces mast cell degranulation without changing intracellular calcium levels | |
| CN1022323C (zh) | 从外消旋体中分离咪唑衍生物的d-对映体的方法 | |
| ES2234597T3 (es) | Uso de antagonistas del receptor de la dopamina d 3 para la produccion de farmacos para el tratamiento de trastornos de la funcion renal. | |
| US20110218210A1 (en) | Compounds for treating abnormal cellular proliferation | |
| SU873878A3 (ru) | Способ получени производных гидантоина | |
| US20150183736A1 (en) | Cyanine-containing compounds for cancer imaging and treatment | |
| US6545028B2 (en) | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | |
| RU99105211A (ru) | Арилалканоилпиридазины | |
| JP2007511203A5 (ru) | ||
| Zatz | Relationship between light, calcium influx and cAMP in the acute regulation of melatonin production by cultured chick pineal cells | |
| Bering et al. | Muscarinic cholinergic receptors on intact human lymphocytes properties and subclass characterization | |
| Boukhris et al. | Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro | |
| DE602004011578T2 (de) | Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren | |
| Sherline et al. | Catecholamines are mitogenic in 3T3 and bovine aortic endothelial cells. | |
| EA200200650A1 (ru) | Замещенные производные пиперазина в качестве ингибиторов мтр-протеина | |
| Forbes et al. | Role for zinc in a cellular response mediated by protein kinase C in human B lymphocytes | |
| WO2000027832A2 (en) | Thiazole derivatives as ppar gamma ligands | |
| US7326733B2 (en) | Methods for increasing bone density | |
| Sohn et al. | Fentanyl attenuates α1B-adrenoceptor–mediated pulmonary artery contraction | |
| US20030236249A1 (en) | Anti-inflammatory compositions and methods of use | |
| Batra | Comparison of muscarinic acetylcholine binding in the urinary bladder and submandibular gland of the rabbit | |
| Souchet et al. | Impaired regulation of beta2-adrenergic receptor density in mononuclear cells during chronic renal failure | |
| AU2009336141A1 (en) | Combination therapies for neoplastic disorders | |
| CA3157778A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170307 |